Skip to main content
Category

Uncategorized

sbir-sttr-logo

SBIR/STTR Awards in Maryland rank 5th in 2012 – ChooseMaryland.org/SBIR.gov

By Uncategorized

sbir-sttr-logo

In 2012, Maryland ranked 5th in the number and total value of Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) program awards, after California, Massachusetts, Virginia and New York. Maryland firms received 265 awards valued at $94 million. A DBED analysis of SBIR/STTR Phase I and Phase II data shows that the number and value of awards decreased nationally in the last four years, and Maryland followed this trend. Even so, when compared to other states, Maryland consistently ranked within the top five recipients of SBIR/STTR awards in both the number and the dollar value of awards received.

Read More
mimetas

MIMETAS Appoints Biotech Pioneer Herbert Heyneker as Chairman of the Board

By Uncategorized

mimetasMIMETAS today announces the appointment of Herbert L. Heyneker, Ph.D. as Chairman of the Board of Directors. Dr. Heyneker will be supporting MIMETAS in her mission to develop high-throughput Organ-on-a-Chip products for predictive therapy testing.

“Organ-on-a-Chip technology is extremely hot in the United States today. But none of the technologies I’ve seen so far comes even close to the level of elegance and sophistication that MIMETAS is offering.” says Herb Heyneker, who is based in the San Francisco Bay area. “I am strongly convinced that MIMETAS technology has the potential to create a revolution in medicine development and therapy selection. […]”

Read Full Article

national-brain-tumor-society

Advancing Research to Therapies for Brain Tumors Conference Connects Academic Scientists to Industry Investors

By Uncategorized

national-brain-tumor-society

National Brain Tumor Society’s inaugural event draws over 100 brain tumor researchers, biopharma executives, government officials, and venture capital investors

National Brain Tumor Society, the largest nonprofit in the United States dedicated to the brain tumor community, recently hosted the inaugural Advancing Research to Therapies (ART) for Brain Tumors Conference in Washington, D.C. The ART Conference brought together more than 100 leading experts from academic research labs, government agencies, biotech and pharmaceutical companies, and venture capital firms to increase communication and collaboration, as well as discuss licensing and investment criteria for new drug candidates to speed the discovery of new treatments for brain tumor patients.

Read More

NINDS Phase III Investigator-Initiated Efficacy Clinical Trials (U01)

By Uncategorized

Funding Opportunity Number: PAR-13-278
Opportunity Category: Discretionary
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
CFDA Number: 93.583
Eligible Applicants State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Agency Name: HHS-NIH11
Closing Date: Sep 07, 2016
Award Ceiling:
Expected Number of Awards:
Creation Date: Jul 22, 2013
Funding Opportunity Description: The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for submitting grant applications to conduct multi-site, randomized, controlled, Phase 3 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials may address questions within the mission and research interests of the NINDS. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/).

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=238034

Read More
Regional Project The University System of Maryland Northrop Grumman BHEF

Regional Project: The University System of Maryland, Northrop Grumman | BHEF

By Uncategorized

Regional Project The University System of Maryland Northrop Grumman BHEF

The University System of Maryland is leading a multi-campus effort to bring the unique resources of institutions in the system to address Maryland’s STEM workforce needs. The University of Maryland, College Park in partnership with Northrop Grumman is creating the nation’s first undergraduate multidisciplinary residential cybersecurity honors program. The University of Maryland, Baltimore County (UMBC) is developing a project that connects STEM undergraduates to new career pathways by applying their knowledge to innovation and entrepreneurship, which will begin with a focus on chemistry and link STEM undergraduate education to business, R&D, and innovation.

Read More
BioPharm

Media Alert: Leading Local Biotech Firms to Host Aspiring Young Scientists Next Week | Fort Mill Times – Fort Mill, SC

By Uncategorized

BioPharm

Montgomery County’s top biotechnology firms will open their doors and their state-of-the-art laboratories next week to local middle school students interested in the life sciences. In a partnership with MdBio Foundation, Inc., and Montgomery College, preeminent local scientists and executives from MedImmune, Qiagen and Emergent BioSolutions will share their expertise and career stories with students from the Young Science Explorers Program (YSEP), a weeklong science workshop for rising seventh and eighth grade students.

Dressed in lab coats and safety glasses, students will get once in a lifetime exposure to local companies and scientists on the leading edge of medical breakthroughs. Topics will range from microbiology and vaccine research to lab safety and potential career paths for science students.

Read More
bhi-logo

BHI Internship Program: Positions Available

By Uncategorized

bhi-logo

BioHealth Innovation, Inc., (BHI) a non-profit organization which strives to facilitate the development of commercially viable health IT products and companies by connecting market relevant research assets to appropriate funding, management and markets, is seeking interns as part of the BHI Internship Program.

POSITION DESCRIPTION – BHI Intern

BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, is seeking highly motivated and dynamic individuals to fill internship positions at the Rockville, MD headquarters.  The BHI Internship Program offers essential experience for IT, Business, and Biohealth students in the region.  By offering a variety of projects and responsibilities to students, BHI aims to prepare interns for professional careers in the business, life sciences, healthcare and IT industries.

Read More

NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44)

By Uncategorized

Funding Opportunity Number: PAR-13-250
Opportunity Category: Discretionary
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
CFDA Number: 93.855
93.856
Eligible Applicants Small businesses
Agency Name: HHS-NIH11
Closing Date: May 13, 2016
Award Ceiling:
Expected Number of Awards:
Creation Date: Jun 24, 2013
Funding Opportunity Description: This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program will utilize the cooperative agreement mechanism (U44) to enable support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and can be proposed under this program. However, not more than one clinical trial should be proposed within each grant application. The NIAID has a robust infrastructure for conducting clinical studies that includes independently managed resources provided through grants and contracts, as well as resources that are integrated within existing NIAID-supported clinical trial networks. Proposed clinical trials may use NIAIDs independent infrastructure for clinical studies, however, support will not be provided for studies that propose to use dedicated resources that are part of a NIAID-supported clinical trial network. A Commercialization Plan must be included that details plans for promoting further commercialization of the intervention/product/technology to be derived from or associated with the proposed clinical trial, including plans for promoting and establishing partnerships between the SBIR Phase II awardee and third-party investors and/or strategic partners.

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=236728

Read More

Revolutionary Genome Sequencing Technologies The $1000 Genome (R01)

By Uncategorized

Funding Opportunity Number: RFA-HG-13-005
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
CFDA Number: 93.172
Eligible Applicants State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Agency Name: HHS-NIH11
Closing Date: Oct 17, 2013
Award Ceiling: $1,000,000
Expected Number of Awards:
Creation Date: Jun 26, 2013
Funding Opportunity Description: The National Human Genome Research Institute (NHGRI) solicits R01 grant applications to develop novel technologies that will enable extremely low-cost, high quality DNA sequencing. The goal of this initiative is to reduce the cost of sequencing a mammalian-sized genome to approximately $1000. Applicants may propose to develop full-scale sequencing systems or to investigate challenges underlying key system components. Exploration of methods other than those currently being pursued as potential $1,000 genome technologies is encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=236793

Read More

Revolutionary Genome Sequencing Technologies The $1000 Genome (SBIR [R43/R44])

By Uncategorized

Funding Opportunity Number: RFA-HG-13-007
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
CFDA Number: 93.172
Eligible Applicants Small businesses
Agency Name: HHS-NIH11
Closing Date: Oct 17, 2013
Award Ceiling:
Expected Number of Awards:
Creation Date: Jun 26, 2013
Funding Opportunity Description: The National Human Genome Research Institute (NHGRI) solicits SBIR (R43/R44) grant applications to develop novel technologies that will enable extremely low-cost, high quality DNA sequencing. The goal of this initiative is to reduce the cost of sequencing a mammalian-sized genome to approximately $1000. Applicants may propose to develop full-scale sequencing systems or to investigate challenges underlying key system components. Exploration of methods other than those currently being pursued as potential $1,000 genome technologies is encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=236794

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.